James E. Bradner
James Bradner is an institute member and associate director of the Center for the Science of Therapeutics (CSofT) at the Broad Institute. An award-winning hematologist, Bradner develops new therapeutic strategies to treat cancer. The focus of his research is the discovery, optimization, and characterization of small-molecule modulators of gene regulatory pathways. A recognized leader in the development of small-molecule compounds, Bradner is also a prominent advocate for open-source drug discovery.
In addition to his appointment at the Broad, Bradner is an attending physician in the department of Hematology-Oncology at the Dana-Farber Cancer Institute, a member of the affiliated faculty at Harvard Stem Cell Institute of Harvard University, and an assistant professor of medicine at Harvard Medical School.
Bradner is the recipient of numerous awards, including the Damon Runyon-Rachleff Innovation Award, Smith Family Award for Excellence in Biomedical Research, and the Dunkin Donuts Rising Star Award. Bradner attends on the Allogeneic Stem Cell Transplant and Leukemia Services. He is a member of the American Society of Hematology and the American Chemical Society. Bradner is a scientific founder of Acetylon Pharmaceuticals, SHAPE Pharmaceuticals, and Tensha Therapeutics.
Bradner received his M.D. from The University of Chicago Pritzker School of Medicine in 1999. He trained in internal medicine at Brigham and Women’s Hospital and hematology-oncology at Dana-Farber. He completed post-doctoral research training at Harvard University and the Broad Institute.Last updated date: July 2015